论文部分内容阅读
目的:讨论Raf蛋白激酶在肿瘤治疗中的作用。方法:使用PubMed和万方数据库检索,以Raf激酶、抗肿瘤为关键词检索出82篇文章,以与ERK通路、BAY43-9006、ISIS5132、LE-rafAON和MCP1具有相关性的和2006、2007年内发表的为限制筛选25篇文章,以这些文章为基础并扩展文章的参考文献进行讨论。结果:多种拮抗Raf激酶的生物分子的临床研究已深入到不同的阶段,并且得到了较大的进展,其中包括Raf激酶抑制剂-BAY43-9006,反义寡核苷酸ISIS5132、LErafAON、Raf去稳定剂-格尔德霉素以及Ras-Raf的衔接抑制物-MCP1。结论:对于不同部位的肿瘤治疗,Raf激酶可作为单独的攻击靶点或者与传统的化疗方案相结合,而且这两种方式都产生了较有效的作用。
Objective: To discuss the role of Raf protein kinase in tumor therapy. Methods: Using PubMed and Wanfang database, 82 articles were screened out by using Raf kinase and anti-tumor as the key words to correlate with ERK pathway, BAY43-9006, ISIS5132, LE-rafAON and MCP1, and in 2006 and 2007 Published to limit the screening of 25 articles based on these articles and expand the article references for discussion. Results: A large number of clinical studies on biomolecules against Raf kinase have been carried out in different stages and great progress has been made, including RAY kinase inhibitor-BAY43-9006, antisense oligonucleotide ISIS5132, LErafAON, Raf Destabilizer-geldanamycin and the cohesive inhibitor of Ras-Raf-MCP1. CONCLUSIONS: Raf kinase can be used as a single target for therapies in different parts of the tumor or in combination with traditional chemotherapy regimens, both of which have a more potent effect.